• Opportunities and Challenges: Early Development of Immuno-Oncology Therapies

    • Share:
    Name: Opportunities and Challenges: Early Development of Immuno-Oncology Therapies
    Date: May 28, 2020
    Time: 1:00 PM - 1:45 PM EDT
    Event Description:
    Evasion or inhibition of immune surveillance has been shown to be a major mechanism limiting the effectiveness of traditional therapies against tumor cells. However, recent breakthroughs in immuno-oncology research have established that harnessing of the immune system is a powerful way to combat cancer. This panel discussion will address key considerations and challenges in immuno-oncology drug development from discovery research to nonclinical safety assessment.
    In this webinar you will learn about:
    • Pros and cons of different animal models based on mechanism of action
    • Identifying the best study design and endpoints based on target
    • Key considerations when developing a pre-clinical safety assessment strategy to support the first in human clinical trial
    • Pete Gaskin, PhD, ERT, MTOPRA, SENIOR DIRECTOR, Charles River Laboratories
    • Stephen Festin, PhD, Director of Scientific & Commercial Dev., Charles River Laboratories
    • Joseph A. Francisco, PhD, SR Director, Scientific Advisory Services, Charles River Laboratories
    • Patrick Fadden, PhD, Research Director, Charles River Laboratories
    Date/Time Information:
    May 28
    1:00 - 1:45 p.m.
    Contact Information:
    Hosted by LaunchBio
    Set a Reminder:
    Enter your email address below to receive a reminder message.
  • Mark Your Calendars